Zeng L - Search Results

1

Long non-coding RNAs regulate drug resistance in cancer.

Liu K, Gao L, Ma X, Huang JJ, Chen J, Zeng L, Ashby CR Jr, Zou C, Chen ZS. Liu K, et al. Among authors: zeng l. Mol Cancer. 2020 Mar 12;19(1):54. doi: 10.1186/s12943-020-01162-0. Mol Cancer. 2020. PMID: 32164712 Free PMC article. Review.

2

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.

Zhang XY, Zhang YK, Wang YJ, Gupta P, Zeng L, Xu M, Wang XQ, Yang DH, Chen ZS. Zhang XY, et al. Among authors: zeng l. Molecules. 2016 Sep 15;21(9):1236. doi: 10.3390/molecules21091236. Molecules. 2016. PMID: 27649127 Free PMC article.

3

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Zeng L, Gupta P, Chen Y, Wang E, Ji L, Chao H, Chen ZS. Zeng L, et al. Chem Soc Rev. 2017 Oct 2;46(19):5771-5804. doi: 10.1039/c7cs00195a. Chem Soc Rev. 2017. PMID: 28654103 Free PMC article. Review.

4

Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.

Gujarati NA, Zeng L, Gupta P, Chen ZS, Korlipara VL. Gujarati NA, et al. Among authors: zeng l. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4698-4704. doi: 10.1016/j.bmcl.2017.09.009. Epub 2017 Sep 7. Bioorg Med Chem Lett. 2017. PMID: 28916341

5

Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.

Fan YF, Zhang W, Zeng L, Lei ZN, Cai CY, Gupta P, Yang DH, Cui Q, Qin ZD, Chen ZS, Trombetta LD. Fan YF, et al. Among authors: zeng l. Cancer Lett. 2018 May 1;421:186-198. doi: 10.1016/j.canlet.2018.01.021. Epub 2018 Jan 11. Cancer Lett. 2018. PMID: 29331420

6

Oncosis-inducing cyclometalated iridium(iii) complexes.

Guan R, Chen Y, Zeng L, Rees TW, Jin C, Huang J, Chen ZS, Ji L, Chao H. Guan R, et al. Among authors: zeng l. Chem Sci. 2018 May 3;9(23):5183-5190. doi: 10.1039/c8sc01142g. eCollection 2018 Jun 21. Chem Sci. 2018. PMID: 29997872 Free PMC article.

7

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.

Zhang W, Fan YF, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P, Chen ZS. Zhang W, et al. Among authors: zeng l. Front Pharmacol. 2018 Oct 9;9:1097. doi: 10.3389/fphar.2018.01097. eCollection 2018. Front Pharmacol. 2018. PMID: 30356705 Free PMC article.

8

An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.

Zeng L , Li J , Zhang C , Zhang YK , Zhang W , Huang J , Ashby CR , Chen ZS , Chao H . Zeng L , et al. Chem Commun (Camb). 2019 Mar 26;55(26):3833-3836. doi: 10.1039/c9cc00882a. Chem Commun (Camb). 2019. PMID: 30869688

9

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells.

Wang JQ, Li JY, Teng QX, Lei ZN, Ji N, Cui Q, Zeng L, Pan Y, Yang DH, Chen ZS. Wang JQ, et al. Among authors: zeng l. Cancers (Basel). 2020 Feb 18;12(2):466. doi: 10.3390/cancers12020466. Cancers (Basel). 2020. PMID: 32085398 Free PMC article.

10

Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo.

Zhang GN, Gupta P, Wang M, Barbuti AM, Ashby CR Jr, Zhang YK, Zeng L, Xu Q, Fan YF, Chen ZS. Zhang GN, et al. Among authors: zeng l. Cancers (Basel). 2020 Feb 21;12(2):498. doi: 10.3390/cancers12020498. Cancers (Basel). 2020. PMID: 32098067 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,780 results

Search Page

Filters